Outlook Therapeutics Inc OTLK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application
-
Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug
-
Outlook Therapeutics Says FDA Didn't Approve Macular Degeneration Drug Application
-
Outlook Therapeutics Shares Plumb New Depths on FDA Setback
-
Outlook Therapeutics Shares Plummet After FDA Again Rejects Wet AMD Drug
Trading Information
- Previous Close Price
- $1.68
- Day Range
- $1.55–1.68
- 52-Week Range
- $0.16–3.39
- Bid/Ask
- $1.56 / $1.59
- Shares Outstanding
- 148.59M
- Market Cap
- $233.28M
- Volume/Avg
- 7M / 19M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 194.10
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
Valuation
|
Metric
|
OTLK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 194.10 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OTLK
|
|---|---|
Quick Ratio | 0.27 |
Current Ratio | 0.54 |
Interest Coverage | −278.36 |
Quick Ratio
OTLK
Profitability
|
Metric
|
OTLK
|
|---|---|
Return on Assets (Normalized) | −303.61% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
OTLK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|rGf!wFW | LOCK|@$@@D | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$$ggf&g | LOCK|%<^K | $70B | |||
| argenx SE ADR
ARGX
| LOCK|n^kkG$ | LOCK|p>R | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Cqg%%b@ | LOCK|<tc>F | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#@&>jm | LOCK|sj | $36B | |||
| Moderna Inc
MRNA
| LOCK|SvqLfy | LOCK|mQn | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|tw&@@@#Y | LOCK|%J!J$ | $25B | |||
| Incyte Corp
INCY
| LOCK|bjC&<Dr | LOCK|$B | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|w&@w%x | LOCK|><q | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<<qLj> | LOCK|p#R | $17B |
United States